ABOUT ARXIPELAG
Biotechs rarely fail on science alone. They lose time and value where science meets manufacturing, regulation and capital: at the interfaces nobody owns.
OUR STORY
Our story began over ten years ago, advising investment funds and life sciences companies on market entry, acquisitions and portfolio decisions.
Before that, our founder spent 25+ years in pharma operations and program leadership, on every side of the table: engineering contractor, sponsor, CRO quality and global portfolio leadership.
Today, that experience is multiplied by the ArXipelag Network: senior experts who have held senior roles at Novartis, GSK, Pfizer, Sandoz, Sanofi, Takeda and Baxter, as well as in biotechs, CDMOs and CROs.
TRACK RECORD
2 × $500M+
joint-venture programs led end to end in China and South Korea, from strategic decisions to validation
$350M
development portfolio under stage-gate governance, with arbitration at Executive Committee level
FDA · EMA · CFDA
multi-country regulatory programs, plus M&A integration and market entry in Asia
OUR NAME
For every crossing, whether a tech transfer, a due diligence or an integration, ArXipelag assembles the right crew, keeps one senior accountable and brings everyone to the same destination. Simplify the complex.
FOUNDER
25+ years in pharma operations, program and portfolio leadership, including nine years at Baxter International. PMP and Lean Six Sigma Black Belt. Contributor to the PMI standard on value analysis. Works in French, English and Spanish.
Advises investment funds and life sciences companies on market entry, acquisitions and portfolio decisions.
stephane.albecq@simplify-the-complex.com · +33 (0)6 82 16 83 75